

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07F 9/06, C07D 311/04, A61K 9/00, 31/66, 31/35		A1	(11) International Publication Number: WO 00/44757 (43) International Publication Date: 3 August 2000 (03.08.00)
(21) International Application Number: PCT/US00/01923 (22) International Filing Date: 26 January 2000 (26.01.00) (30) Priority Data: 60/117,567 27 January 1999 (27.01.99) US 60/118,198 1 February 1999 (01.02.99) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US 60/117,567 (CIP) Filed on 27 January 1999 (27.01.99) US 60/118,198 (CIP) Filed on 1 February 1999 (01.02.99) (71) Applicant (for all designated States except US): ZIELINSKI LABORATORY [US/US]; Suite C, 10366 Rosell Street, San Diego, CA 92121 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): ZIELINSKI, Jan, E. [DE/US]; 820 Sycamore Avenue, #105, Vista, CA 92083 (US).		(74) Agent: HAILE, Lisa, A.; Gary Cary Ware & Friedenrich LLP, Suite 1600, 4365 Executive Drive, San Diego, CA 92121-2189 (US). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.	
(54) Title: HESPERITIN PRO-FORMS WITH ENHANCED BIOAVAILABILITY			
(57) Abstract <p>A hesperitin pro-form is provided. The invention provides both a hydrophilic and lipophilic hesperetin pro-form. A pharmaceutical composition is provided which is suitable for topical or oral administration in an individual, the composition comprising a hydrophilic hesperetin pro-form and a pharmaceutically acceptable carrier. A pharmaceutical composition is also provided which is suitable for topical or oral administration in an individual, the composition including a lipophilic hesperetin pro-form and a pharmaceutically acceptable carrier. A method is provided for treating a subject having or at risk of having a cell proliferative disorder, including administering to the subject a therapeutically effective amount of a hesperetin pro-form.</p>			